# Norlase

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/norlase-aps

- Industry: Healthcare
- Headquarters: Ballerup, Denmark
- Website: www.norlase.com/
- Total disclosed funding: $11M
- Latest round: Series B (Oct 25, 2021)
- Investors on record: 1

## About

Norlase ApS develops innovative ophthalmic laser technologies, enhancing the efficiency and portability of eye care treatments. Their advanced systems improve patient outcomes across diverse medical settings.Norlase ApS specializes in ophthalmic laser technology, founded in 2024 in Ballerup, Denmark. The company has completed 4 deals and raised a total of USD 11.00 mn in funding, with its latest round occurring in February 2025. The company has not publicly disclosed any significant pivots or changes in business operations. The founder's detailed historical background is unavailable, but their focus remains on developing cutting-edge laser solutions for the ophthalmology market.Norlase specializes in the development and manufacturing of advanced ophthalmic laser technologies designed to enhance the efficiency and portability of eye care treatments. Their primary product offerings include the LYNX, ECHO, LION, and LEAF systems, each contributing unique capabilities to the field of ophthalmology. The LYNX is a pioneering laser indirect ophthalmoscope that introduces pattern scanning capabilities without the need for external consoles, enabling treatments in diverse settings. ECHO incorporates MEMS pattern technology into a compact laser engine, prioritizing portability and ease of use, while LION integrates a battery-powered green laser with a wireless interface for direct ophthalmoscopy. LEAF stands out as a green laser photocoagulator that attaches directly to existing slit lamps, optimizing space and functionality. The company's products cater primarily to ophthalmology clinics and hospitals, with a client base that spans various geographical markets, including Europe and North America, where demand for compact and efficient ophthalmic solutions is rising.Norlase's revenue model is built on the direct sale of its innovative laser systems to medical facilities, primarily ophthalmology practices, through a B2B transaction structure. The company leverages partnerships with distributors to reach a broader client base, ensuring that its technologically advanced products are accessible to eye care professionals. Each flagship product, such as the LION and ECHO, is positioned as a premium offering, with pricing strategies reflecting the advanced capabilities and integrated technologies these systems provide. Given the emphasis on portability and innovation, Norlase’s business transactions focus on delivering value through high-quality medical devices that address specific treatment needs, thereby fostering long-term relationships with healthcare providers in the ophthalmic sector.Norlase ApS plans to launch new products that enhance their existing portfolio, focusing on advanced laser systems tailored for specific ophthalmic applications. The company aims to expand its market presence in regions like Asia and South America by 2026, responding to increased global demand. The recent funding of EUR 20 million raised in February 2025 from the European Investment Bank will facilitate improvements in production capabilities and help the company scale operations to meet customer demand.

## Funding rounds

- Series B, Oct 25, 2021, $11M — West Hill Capital

## Investors

- West Hill Capital (https://capitalatlas.ai/funds/west-hill-capital) — Series B